Last updated December 18, 2021

Diagnostic Accuracy Of CSF 14-3-3 Protein In Sporadic Creutzfeldt-Jakob Disease

Recommendation

For patients who have rapidly progressive dementia and are strongly suspected of having sCJD and for whom diagnosis remains uncertain (pretest probability ∼20%–90%), clinicians should order CSF 14-3-3 assays to reduce the uncertainty of the diagnosis. (B)
300167

Recommendation Grading

Overview

Title

Diagnostic Accuracy Of CSF 14-3-3 Protein In Sporadic Creutzfeldt-Jakob Disease

Authoring Organization

Publication Month/Year

October 2, 2012

Document Type

Guideline

External Publication Status

Published

Country of Publication

US

Document Objectives

To assess the available evidence for the diagnostic accuracy of CSF testing for protein 14-3-3 in patients with suspected sporadic Creutzfeldt-Jakob disease (sCJD).

Inclusion Criteria

Female, Male, Adult, Older adult

Health Care Settings

Ambulatory, Hospice, Hospital, Outpatient

Scope

Assessment and screening, Diagnosis, Management

Diseases/Conditions (MeSH)

D007562 - Creutzfeldt-Jakob Syndrome

Keywords

Creutzfeldt-Jakob disease, subacute spongiform encephalopathy, CJD

Source Citation

Evidence-based guideline: Diagnostic accuracy of CSF 14-3-3 protein in sporadic Creutzfeldt-Jakob disease. Report of the Guideline Development Subcommittee of the American Academy of Neurology. Taim Muayqil, Gary Gronseth, Richard Camicioli. Neurology Oct 2012, 79 (14) 1499-1506; DOI: 10.1212/WNL.0b013e31826d5fc3